MoonLake Immunotherapeutics/$MLTX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
Ticker
$MLTX
Sector
Primary listing
Employees
100
Headquarters
Zug, Switzerland
Website
MLTX Metrics
BasicAdvanced
$896M
-
-$3.33
1.24
-
Price and volume
Market cap
$896M
Beta
1.24
52-week high
$62.75
52-week low
$5.95
Average daily volume
4.6M
Financial strength
Current ratio
8.502
Quick ratio
7.949
Long term debt to equity
25.491
Total debt to equity
26.006
Interest coverage (TTM)
-43.62%
Profitability
EBITDA (TTM)
-226.967
Effective tax rate (TTM)
-0.19%
Management effectiveness
Return on assets (TTM)
-30.72%
Return on equity (TTM)
-54.33%
Valuation
Price to book
2.77
Price to tangible book (TTM)
2.77
Price to free cash flow (TTM)
-4.273
Free cash flow yield (TTM)
-23.40%
Free cash flow per share (TTM)
-2.94
Growth
Earnings per share change (TTM)
155.96%
3-year earnings per share growth (CAGR)
4.66%
MLTX News
AllArticlesVideos
ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTX
Newsfile Corp14 hours ago
Lost Money on MoonLake Immunotherapeutics (MLTX)? Join Class Action Before December 15, 2025 - Contact Levi & Korsinsky
Newsfile Corp18 hours ago
MOONLAKE INVESTORS: MoonLake Immunotherapeutics (MLTX) has been Sued for Securities Fraud, Investors are Urged to Contact BFA Law
Newsfile Corp1 day ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MoonLake Immunotherapeutics stock?
MoonLake Immunotherapeutics (MLTX) has a market cap of $896M as of November 15, 2025.
What is the P/E ratio for MoonLake Immunotherapeutics stock?
The price to earnings (P/E) ratio for MoonLake Immunotherapeutics (MLTX) stock is 0 as of November 15, 2025.
Does MoonLake Immunotherapeutics stock pay dividends?
No, MoonLake Immunotherapeutics (MLTX) stock does not pay dividends to its shareholders as of November 15, 2025.
When is the next MoonLake Immunotherapeutics dividend payment date?
MoonLake Immunotherapeutics (MLTX) stock does not pay dividends to its shareholders.
What is the beta indicator for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics (MLTX) has a beta rating of 1.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.